ClinicalTrials.gg
Not yet recruitingNCT07923734Updated Nov 6, 2026

Study of Electrocardiogram (ECG) Safety of Sezaby in Neonatal Seizures

A Phase 4 interventional study of Sezaby in Neonatal Seizure, sponsored by Sun Pharma Advanced Research Company Limited. Not yet recruiting at 1 site in United States. Open to participants aged 0 Days to 27 Days. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Sun Pharma Advanced Research Company Limited (formerly part of Sun Pharmaceutical Industries Limited) · Phase 4, Interventional, and Other

Updated Nov 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
0 Days to 27 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.

Planned enrollment
170th of 306
45 · median 56
Started
2026
with 14 others
Phase 4
36 of 395
4 open now
Primary completion
2028-03
later than 56 of 91 live
Registered
395th of 395
by date

Among the 395 studies in Seizures with a site in United States, this one is the 170th largest by planned enrollment of the 306 interventional ones that give a count, is one of 15 that started in 2026, is one of 36 in phase 4, reaches primary completion later than 56 of the 91 other live ones, and was the 395th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 0 Days to 27 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Seizures with a site in United States, or all of them as a file.
02

Study summary

This Phase 4, multicenter, single-arm, open-label study evaluates the effect of intravenous Sezaby (phenobarbital sodium) on electrocardiographic safety, including the QT interval, in neonates with seizures.

Read the detailed description

This Phase 4, multicenter, single-arm, open-label study evaluates the effect of Sezaby on electrocardiographic safety, including the QT interval, in neonates with seizures. Participants will receive intravenous Sezaby and undergo electrocardiographic and safety assessments during treatment.

03

Conditions studied

  • Neonatal Seizure

Browse trials for

04

Who can participate

Ages eligible
0 Days to 27 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Neonates with seizures confirmed by continuous electroencephalogram (cEEG) monitoring.
  2. Acute symptomatic seizure etiologies other than correctable metabolic abnormalities.
  3. Term or preterm infants with postnatal age less than 28 days.
  4. Body weight of at least 1 kg.
  5. Written from a parent or legal guardian.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with anticonvulsant medications.
  2. Correctable metabolic abnormalities associated with seizure cessation when corrected.
  3. Baseline corrected using Fridericia's formula (QTcF) greater than 450 milliseconds.
  4. Significant risk factors for torsade de pointes, including congenital long QT syndrome or significant cardiac disease.
  5. Renal failure.
  6. Acute porphyria.
  7. Neonates in whom death is considered imminent in the opinion of the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Sezaby

    Neonates with seizures receiving intravenous Sezaby administered as loading dose(s) followed by maintenance dosing for up to 5 days according to the study protocol.

    Drug: Sezaby

Interventions

  • DrugSezaby

    Sezaby (phenobarbital sodium for injection) is administered as intravenous loading and maintenance doses over a treatment period of up to 5 days for the treatment of neonatal seizures.

    Also known as: Phenobarbital sodium

06

What researchers measure

Primary outcomes

  1. Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF)

    Change from baseline in QT interval corrected for heart rate using Fridericia's formula (QTcF) following treatment with Sezaby. QTcF values will be assessed from electrocardiogram recordings obtained during the treatment period.

    Time frame: Baseline through Day 5

Secondary outcomes

  1. Change From Baseline in QT Interval Corrected Using Bazett's Formula (QTcB)

    Change from baseline in QT interval corrected for heart rate using Bazett's formula (QTcB) following treatment with Sezaby.

    Time frame: Baseline through Day 5

  2. Incidence of Treatment-Emergent Adverse Events

    Assessment of safety based on the incidence of treatment-emergent adverse events (TEAEs) following administration of Sezaby.

    Time frame: First dose through Safety Follow-up (approximately 20 days)

  3. Change From Baseline in QTcF and QTcB Intervals in Participants With Hypoxic-Ischemic Encephalopathy (HIE) Compared With Participants Without HIE

    Change from baseline in QT interval corrected using Fridericia's formula (QTcF) and Bazett's formula (QTcB) in participants with HIE compared with participants without HIE following treatment with Sezaby.

    Time frame: Baseline through Day 5

  4. Frequency of Treatment-Emergent Changes in Electrocardiogram Morphology

    Frequency of treatment-emergent changes in electrocardiogram (ECG) morphology following treatment with Sezaby.

    Time frame: Baseline through Day 5

  5. Incidence of Categorical Outliers in QTcF, QTcB, Heart Rate, PR Interval, and QRS Interval

    Incidence of categorical outliers in QT interval corrected using Fridericia's formula (QTcF), QT interval corrected using Bazett's formula (QTcB), heart rate (HR), PR interval, and QRS interval following treatment with Sezaby.

    Time frame: Baseline through Day 5

  6. Plasma Concentration of Phenobarbital

    Assessment of plasma concentrations of phenobarbital following administration of Sezaby.

    Time frame: Baseline through Day 5

  7. A. Correlation Between Post-Conceptional Age and Change From Baseline in QTcF

    Correlation between post-conceptional age, measured in completed weeks, and change from baseline in the QT interval corrected using Fridericia's formula (QTcF), measured in milliseconds from centrally evaluated continuous 12-lead electrocardiogram recordings. A correlation coefficient will be calculated across participants separately at each protocol-specified ECG assessment time point.

    Time frame: Baseline through Day 5

  8. B. Correlation Between Post-Conceptional Age and Change From Baseline in QTcB

    Correlation between post-conceptional age, measured in completed weeks, and change from baseline in the QT interval corrected using Bazett's formula (QTcB), measured in milliseconds from centrally evaluated continuous 12-lead electrocardiogram recordings. A correlation coefficient will be calculated across participants separately at each protocol-specified ECG assessment time point.

    Time frame: Baseline through Day 5

  9. A. Correlation Between Serum Sodium Concentration and Change From Baseline in QTcF

    Correlation between daily serum sodium concentration, measured by the clinical laboratory (mmol/L), and change from baseline in the QT interval corrected using Fridericia's formula (QTcF), measured in milliseconds from centrally evaluated continuous 12-lead electrocardiogram recordings. A correlation coefficient will be calculated across participants separately for each protocol-specified ECG assessment time point.

    Time frame: Baseline through Day 5

  10. B. Correlation Between Serum Sodium Concentration and Change From Baseline in QTcB

    Correlation between daily serum sodium concentration, measured by the clinical laboratory (mmol/L), and change from baseline in the QT interval corrected using Bazett's formula (QTcB), measured in milliseconds from centrally evaluated continuous 12-lead electrocardiogram recordings. A correlation coefficient will be calculated across participants separately for each protocol-specified ECG assessment time point.

    Time frame: Baseline through Day 5

  11. C. Correlation Between Serum Potassium Concentration and Change From Baseline in QTcF

    Correlation between daily serum potassium concentration, measured by the clinical laboratory (mmol/L), and change from baseline in the QT interval corrected using Fridericia's formula (QTcF), measured in milliseconds from centrally evaluated continuous 12-lead electrocardiogram recordings. A correlation coefficient will be calculated across participants separately for each protocol-specified ECG assessment time point.

    Time frame: Baseline through Day 5

  12. D. Correlation Between Serum Potassium Concentration and Change From Baseline in QTcB

    Correlation between daily serum potassium concentration, measured by the clinical laboratory (mmol/L), and change from baseline in the QT interval corrected using Bazett's formula (QTcB), measured in milliseconds from centrally evaluated continuous 12-lead electrocardiogram recordings.

    Time frame: Baseline through Day 5

  13. E. Correlation Between Serum Calcium Concentration and Change From Baseline in QTcF

    Correlation between daily serum calcium concentration, measured by the clinical laboratory (mg/dL or mmol/L per protocol laboratory reporting), and change from baseline in the QT interval corrected using Fridericia's formula (QTcF), measured in milliseconds from centrally evaluated continuous 12-lead electrocardiogram recordings.

    Time frame: Baseline through Day 5

  14. F. Correlation Between Serum Calcium Concentration and Change From Baseline in QTcB

    Correlation between daily serum calcium concentration, measured by the clinical laboratory (mg/dL or mmol/L per protocol laboratory reporting), and change from baseline in the QT interval corrected using Bazett's formula (QTcB), measured in milliseconds from centrally evaluated continuous 12-lead electrocardiogram recordings.

    Time frame: Baseline through Day 5

  15. A. Correlation Between Body Temperature and Change From Baseline in QTcF

    Correlation between body temperature, measured in degrees Celsius at or near each protocol-specified ECG assessment, and change from baseline in the QT interval corrected using Fridericia's formula (QTcF), measured in milliseconds from centrally evaluated continuous 12-lead electrocardiogram recordings. A correlation coefficient will be calculated across participants separately at each protocol-specified ECG assessment time point.

    Time frame: Baseline through Day 5

  16. B. Correlation Between Body Temperature and Change From Baseline in QTcB

    A correlation coCorrelation between body temperature, measured in degrees Celsius at or near each protocol-specified ECG assessment, and change from baseline in the QT interval corrected using Bazett's formula (QTcB), measured in milliseconds from centrally evaluated continuous 12-lead electrocardiogram recordings. A correlation coefficient will be calculated across participants separately at each protocol-specified ECG assessment time point.efficient will be calculated across participants separately at each protocol-specified ECG assessment time point.

    Time frame: Baseline through Day 5

07

Study locations

1 site
  • Site 1
    Detroit, Michigan 48201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2028, 15 months later.

Of 26 phase 4 interventional studies under Seizures, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Nov 6, 2026
StartEst.
Dec 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07923734
Responsible party
Sponsor
First posted
Nov 6, 2026
Start date
Dec 2026 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Clinical Development
Contact
clinical.trials@sparcmail.com
9122 66455645

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phenobarbital

Start the discussion